InsidersTradesSigma
Total declarations
Companies
▲ Purchases (19 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
19
Disclosed sells
0
T+90 hit rate
45%
T+90 mean return
-1.3%
Across 20 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Galante Joseph C, Director. Insider active across 3 companies, notably Cumberland Pharmaceuticals INC. Aggregated, 31 filings have been logged. Split: 19 buys · 0 sell. Total volume traded: €71k. Activity tracked since 17 March 2021. The latest transaction was filed on 17 March 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations31 total
1,000 shares@ US$5.1719.3% of flowCommon StockSEC:0001628280-25-013541:0
2,500 shares@ US$1.7116.1% of flowCommon StockSEC:0001628280-25-003185:0
1,000 shares@ US$1.716.4% of flowCommon StockSEC:0001214659-24-005222:0
239 shares@ US$82.7215.9% of flowPNFP Common StockSEC:0001115055-24-000054:0
1,000 shares@ US$1.927.2% of flowCommon StockSEC:0001209191-23-021278:0
174 shares@ US$74.0910.6% of flowPNFP Common StockSEC:0001567619-23-004174:0
1,000 shares@ US$72.2657.8% of flowPNFP Common StockSEC:0001567619-23-001121:0
Ideal exit: 17 Oct 2023 (T+270)
65 shares@ US$2.530.7% of flowCommon StockSEC:0001209191-22-062643:0
Ideal exit: 29 Jul 2023 (T+270)
65 shares@ US$2.330.6% of flowCommon StockSEC:0001209191-22-062651:0
Ideal exit: 28 Aug 2023 (T+270)
65 shares@ US$2.570.7% of flowCommon StockSEC:0001209191-22-057942:0
Ideal exit: 24 Jun 2023 (T+270)
65 shares@ US$2.350.6% of flowCommon StockSEC:0001209191-22-051667:0
Ideal exit: 13 May 2023 (T+270)
70 shares@ US$2.110.6% of flowCommon StockSEC:0001209191-22-046896:0
Ideal exit: 28 Mar 2023 (T+270)
76 shares@ US$2.050.0002% mcap1.2% of flowCommon StockSEC:0001209191-22-040094:0
Ideal exit: 26 Feb 2023 (T+270)
61 shares@ US$2.450.0002% mcap1.2% of flowCommon StockSEC:0001209191-22-035994:0
Ideal exit: 27 Jan 2023 (T+270)
56 shares@ US$2.710.0002% mcap1.2% of flowCommon StockSEC:0001209191-22-027646:0
Ideal exit: 9 Jan 2023 (T+270)
1,000 shares@ US$2.590.0029% mcap20.1% of flowCommon StockSEC:0001209191-22-026138:0
201 shares@ US$101.08100.0% of flowPNFP Common StockSEC:0001567619-22-006185:0
142 shares@ US$2.670.0004% mcap2.8% of flowCommon StockSEC:0001209191-21-067899:0
Ideal exit: 29 Jul 2022 (T+270)
142 shares@ US$2.671.3% of flowCommon StockSEC:0001209191-21-067899
Ideal exit: 29 Jul 2022 (T+270)
142 shares@ US$2.691.3% of flowCommon StockSEC:0001209191-21-063235
Ideal exit: 28 Jun 2022 (T+270)
142 shares@ US$2.690.0004% mcap2.8% of flowCommon StockSEC:0001209191-21-063235:0
Ideal exit: 28 Jun 2022 (T+270)
142 shares@ US$2.880.0004% mcap2.9% of flowCommon StockSEC:0001209191-21-058530:0
Ideal exit: 29 May 2022 (T+270)
142 shares@ US$2.881.4% of flowCommon StockSEC:0001209191-21-058530
Ideal exit: 29 May 2022 (T+270)
142 shares@ US$3.340.0005% mcap3.4% of flowCommon StockSEC:0001209191-21-055485:0
Ideal exit: 29 Apr 2022 (T+270)
142 shares@ US$3.341.6% of flowCommon StockSEC:0001209191-21-055485
Ideal exit: 29 Apr 2022 (T+270)
25 of 31 declarations
About Galante Joseph C
Joseph C. Galante is an executive at Cumberland Pharmaceuticals Inc.
